Skip to content

Editors

Harry Cassin
Publisher and Editor

Andy Spalding
Senior Editor

Jessica Tillipman
Senior Editor

Bill Steinman
Senior Editor

Richard L. Cassin
Editor at Large

Elizabeth K. Spahn
Editor Emeritus

Cody Worthington
Contributing Editor

Julie DiMauro
Contributing Editor

Thomas Fox
Contributing Editor

Marc Alain Bohn
Contributing Editor

Bill Waite
Contributing Editor

Shruti J. Shah
Contributing Editor

Russell A. Stamets
Contributing Editor

Richard Bistrong
Contributing Editor

Eric Carlson
Contributing Editor

Giant corporations are good for compliance

Most of us, if we have any sense at all, harbor some healthy distrust of the world’s biggest companies. For good reason we fear the concentrated power of giant corporations. What, after all, is one person compared to the overwhelming might of Facebook, Walmart, or Exxon?… Continue Reading

Job: Counsel-Litigation and Legal Compliance (Eli Lilly, USA)

Job Title: Counsel-Litigation and Legal Compliance

Employer: Eli Lilly

Location: Indianapolis, Indiana USA

 

Description

Lawyer on global Litigation and Legal Compliance team, with focus on international investigations and litigation, global anti-corruption counseling, privileged internal and government investigations, and counseling the Compliance organization. … Continue Reading

FCPA enforcement report for Q1 2015

During the first calendar quarter, there were two corporate FCPA enforcement actions — both through SEC administrative orders — and one individual resolution.

(Last year in Q1 there were two corporate enforcement actions and two individual Siemens-related actions).… Continue Reading

DOJ declination for Merck

Big-pharma Merck said an SEC filing Thursday that the DOJ has closed its FCPA investigation of the company.

Merck first disclosed in 2010 that it received letters from the DOJ and SEC asking for FCPA-related information about its activities in a number of countries.… Continue Reading

U.S., China enforcement crossfire creates new risks

At the beginning of this year, China’s president Xi Jinping promised to fight both “tigers” and “flies” — high-ranking and low-ranking corrupt officials — in his crackdown on corruption. Since then, the anti-graft campaign has led to the conviction of Bo Xilai and to the front-page investigations of foreign companies in the pharmaceutical and oil and gas sectors, among others.… Continue Reading

Drug sellers ‘take vacations’ amid China anti-graft campaign

Pharmas have told their sales teams to halt all activity in China to avoid being caught in the nationwide “enforcement storm,” according to the Guangdong-based Yangcheng Evening News.

“It is rumored that police in plain clothes are patrolling in hospitals; drug sales representatives will be fined 500 yuan ($81) and regional sales managers 1000 yuan ($162) once being caught in hospitals,” an unidentified sales representative told the paper.Continue Reading